Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma

Next Previous
X
Search
Trial Profile

A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Tigilanol tiglate (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors QBiotics

    • Most Recent Events

    • 13 Apr 2023 Status changed from recruiting to discontinued.
    • 14 Feb 2023 According to a QBiotics media release, following completion of a review of its human clinical oncology programme, the Company has resolved to close its melanoma clinical trials; the tigilanol tiglate monotherapy study QB46C-H04, and the tigilanol tiglate pembrolizumab combination study QB46C-H06 will be discontinued.
    • 14 Oct 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top